{"id":32471,"date":"2025-04-26T00:51:48","date_gmt":"2025-04-25T16:51:48","guid":{"rendered":"https:\/\/flcube.com\/?p=32471"},"modified":"2025-04-26T00:51:49","modified_gmt":"2025-04-25T16:51:49","slug":"hefei-lifeon-gains-nmpa-approval-for-nexletol-clinical-trials-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32471","title":{"rendered":"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China"},"content":{"rendered":"\n<p>China-based Hefei Lifeon Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/003020:SHE\">SHE: 003020<\/a>) announced that it has received clinical trial approval from China&#8217;s National Medical Products Administration (NMPA) for its generic version of Esperion Therapeutics&#8217; Nexletol (bempedoic acid). The drug, an adenosine triphosphate-citrate lyase (ACL) inhibitor, will be evaluated in two key scenarios: as an adjunctive therapy with existing LDL-C lowering regimens and as a monotherapy for patients intolerant to statins.<\/p>\n\n\n\n<p><strong>Clinical Trial Details<\/strong><br>The Phase III trial (CTR2024XXXX) will enroll patients with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia (HeFH). This study aims to assess the safety and efficacy of Nexletol in these patient populations, providing valuable data for its potential use in China.<\/p>\n\n\n\n<p><strong>Market Context<\/strong><br>Nexletol, approved in the US in 2020, is not yet available in China. However, Huayi Pharma and Gan &amp; Lee Pharma are currently investigating their own generic versions in clinical trials. Lifeon&#8217;s approval marks a significant step toward bringing this innovative therapy to the Chinese market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32473,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1728,31,4035,4034],"class_list":["post-32471","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-esperion-therapeutics","tag-generic-drugs","tag-lifeon-pharmaceutical","tag-she-003020"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for its generic version of Esperion Therapeutics&#039; Nexletol (bempedoic acid). The drug, an adenosine triphosphate-citrate lyase (ACL) inhibitor, will be evaluated in two key scenarios: as an adjunctive therapy with existing LDL-C lowering regimens and as a monotherapy for patients intolerant to statins.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32471\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China\" \/>\n<meta property=\"og:description\" content=\"China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for its generic version of Esperion Therapeutics&#039; Nexletol (bempedoic acid). The drug, an adenosine triphosphate-citrate lyase (ACL) inhibitor, will be evaluated in two key scenarios: as an adjunctive therapy with existing LDL-C lowering regimens and as a monotherapy for patients intolerant to statins.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32471\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-25T16:51:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-25T16:51:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China\",\"datePublished\":\"2025-04-25T16:51:48+00:00\",\"dateModified\":\"2025-04-25T16:51:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2602.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Esperion Therapeutics\",\"Generic drugs\",\"Lifeon Pharmaceutical\",\"SHE: 003020\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32471#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32471\",\"name\":\"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2602.webp\",\"datePublished\":\"2025-04-25T16:51:48+00:00\",\"dateModified\":\"2025-04-25T16:51:49+00:00\",\"description\":\"China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its generic version of Esperion Therapeutics' Nexletol (bempedoic acid). The drug, an adenosine triphosphate-citrate lyase (ACL) inhibitor, will be evaluated in two key scenarios: as an adjunctive therapy with existing LDL-C lowering regimens and as a monotherapy for patients intolerant to statins.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32471\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Explore the latest insights on Lifeon Pharmaceutical and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lifeon Pharmaceutical's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32471#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its generic version of Esperion Therapeutics' Nexletol (bempedoic acid). The drug, an adenosine triphosphate-citrate lyase (ACL) inhibitor, will be evaluated in two key scenarios: as an adjunctive therapy with existing LDL-C lowering regimens and as a monotherapy for patients intolerant to statins.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32471","og_locale":"en_US","og_type":"article","og_title":"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China","og_description":"China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its generic version of Esperion Therapeutics' Nexletol (bempedoic acid). The drug, an adenosine triphosphate-citrate lyase (ACL) inhibitor, will be evaluated in two key scenarios: as an adjunctive therapy with existing LDL-C lowering regimens and as a monotherapy for patients intolerant to statins.","og_url":"https:\/\/flcube.com\/?p=32471","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-25T16:51:48+00:00","article_modified_time":"2025-04-25T16:51:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32471#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32471"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China","datePublished":"2025-04-25T16:51:48+00:00","dateModified":"2025-04-25T16:51:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32471"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32471#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2602.webp","keywords":["Clinical trial approval \/ initiation","Esperion Therapeutics","Generic drugs","Lifeon Pharmaceutical","SHE: 003020"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32471#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32471","url":"https:\/\/flcube.com\/?p=32471","name":"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32471#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32471#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2602.webp","datePublished":"2025-04-25T16:51:48+00:00","dateModified":"2025-04-25T16:51:49+00:00","description":"China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its generic version of Esperion Therapeutics' Nexletol (bempedoic acid). The drug, an adenosine triphosphate-citrate lyase (ACL) inhibitor, will be evaluated in two key scenarios: as an adjunctive therapy with existing LDL-C lowering regimens and as a monotherapy for patients intolerant to statins.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32471#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32471"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32471#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2602.webp","width":1080,"height":608,"caption":"Explore the latest insights on Lifeon Pharmaceutical and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lifeon Pharmaceutical's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com."},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32471#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32471"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32471\/revisions"}],"predecessor-version":[{"id":32474,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32471\/revisions\/32474"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32473"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}